Great Novel Therapeutics Biotech & Medicals Past Earnings Performance
Past criteria checks 0/6
Great Novel Therapeutics Biotech & Medicals's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 53.5% per year.
Key information
-18.9%
Earnings growth rate
5.6%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 53.5% |
| Return on equity | -10.0% |
| Net Margin | -1,268.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Great Novel Therapeutics Biotech & Medicals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -62 | 18 | 51 |
| 30 Sep 23 | 5 | -61 | 18 | 51 |
| 30 Jun 23 | 5 | -61 | 19 | 50 |
| 31 Mar 23 | 3 | -58 | 20 | 44 |
| 31 Dec 22 | 1 | -56 | 19 | 39 |
| 30 Sep 22 | 1 | -51 | 18 | 35 |
| 30 Jun 22 | 1 | -47 | 18 | 32 |
| 31 Mar 22 | 1 | -41 | 18 | 25 |
| 31 Dec 21 | 1 | -36 | 18 | 19 |
| 30 Sep 21 | 0 | -36 | 16 | 19 |
| 30 Jun 21 | 0 | -36 | 15 | 19 |
| 31 Mar 21 | 0 | -34 | 13 | 19 |
| 31 Dec 20 | 0 | -31 | 10 | 19 |
| 30 Sep 20 | 0 | -29 | 10 | 19 |
| 30 Jun 20 | 0 | -27 | 10 | 18 |
| 31 Mar 20 | 0 | -29 | 10 | 19 |
| 31 Dec 19 | 0 | -30 | 10 | 21 |
| 31 Dec 18 | 3 | -36 | 10 | 30 |
| 31 Dec 14 | 0 | -21 | 10 | 13 |
| 31 Dec 13 | 0 | -7 | 5 | 2 |
Quality Earnings: 7427 is currently unprofitable.
Growing Profit Margin: 7427 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7427 is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare 7427's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7427 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.1%).
Return on Equity
High ROE: 7427 has a negative Return on Equity (-9.96%), as it is currently unprofitable.